The lack of SMO expression in CSCs may partly explain the lack of benefit in lung cancer associated with the addition of SMO inhibitor to chemotherapy regimens, but there is yet to be a study to elucidate the importance of SMO/GLI in promoting chemoresistance in the context of CSC in lung cancer. This evidence concerns the gene GLI1 and lung carcinoma.